📍We’re really excited to be here at DCAT (Drug, Chemical & Associated Technologies Association) [...]

📍We’re really excited to be here at DCAT (Drug, Chemical & Associated Technologies Association) New York 2026! 
 
🎯Type I glass is becoming the material of choice for the global nasal market ($10.3bn) as more advanced and long-term treatments for Alzheimer’s, Parkinsons, multiple sclerosis and depression, require primary packaging combining sterility, consistency and precision dosing. 
 
📣We are proud to announce our collaboration with Prince Sterilization Services, LLC to validate Ready-to-Use (RTU) Type I glass primary packaging solutions serving the North American market. 
 
We’re showcasing:

✅ My Sterinity Nasal – the first platform to launch from the collaboration between SGD Pharma and Prince Sterilization Services LLC, combining SGD Pharma’s leadership in Type I glass manufacture and Prince’s expertise in sterilization services. 
 
✅ SEALIAN – high-performance internal surface treatment that provides enhanced chemical durability and superior protection for sensitive drugs. 
 
✅ IDENCY – premium vials exhibit a higher chemical and mechanical resistance than standard tubular vials and are designed to have the same outer diameter to enable integration with existing filling lines.
 
💡Whether you’re qualifying suppliers, scaling production, or exploring new collaborations, we’d love to discuss how SGD Pharma can help secure your supply chain and support your growth. Our team is here ready to connect and answer your questions!

Tristan Bauer, Claus Meilinger, Sergio Sato, Francois Billard, Heather Moore, Massine Yanat, Ana Sabillon, Nicolas Barda, Fabio Invernizzi - Change Management, Robert Apgar, Carole Grassi Mircich
 
SGDPharma DCAT2026 TypeIGlass PharmaceuticalPackaging SupplySecurity Innovation Injectables NasalDrugDelivery RTU